This company develops engineered antibody fragments for diagnostic imaging and radioimmunotherapy, targeting prostate, bladder, and pancreatic cancers. These fragments offer healthcare professionals new tools for understanding and treating cancer with immuno-oncology therapies.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing cancer treatment effectiveness often rely on repeat, painful biopsies, which may not accurately represent the immune status of the entire tumor. This can lead to delayed insights into treatment response and potentially less effective patient care paths.
Solution
ImaginAb provides advanced immuno-oncology imaging solutions, including CD8 ImmunoPET, to visualize and quantify CD8 T-cells in vivo. Their technology utilizes minibody antibodies to scan patients, delivering a comprehensive immune profile before, during, and after treatment. This non-invasive approach offers physicians precise, timely immune response data, enabling smarter decisions on treatment paths and improving patient comfort. By providing a whole-body measurement of CD8 cells, ImaginAb's technology helps identify treatment responses earlier, potentially reducing costs and improving patient outcomes.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies, clinical investigators, and healthcare providers focused on immuno-oncology and in need of advanced imaging tools to assess treatment response and guide clinical decision-making.
Features
- CD8 ImmunoPET imaging agent (89Zr crefmirlimab berdoxam) for PET imaging of CD8 T-cells
- Minibody antibody technology for whole-body scanning
- Non-invasive assessment of immune response status
- Identification of treatment response earlier than traditional methods
- Support for clinical trials in North America, Europe, and Australia
- Expert support for implementation and imaging protocols (ICF, IND, IRB, user training)
- Partnerships with pharmaceutical and biotech companies for clinical development programs